Literature DB >> 10100725

Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.

C Pellat-Deceunynck1, G Jego, J L Harousseau, H Vié, R Bataille.   

Abstract

Peripheral blood T cells from a patient with multiple myeloma in complete remission were selected in vitro against an autologous myeloma cell line (SBN-1), using a protocol designed for the selection of relatively rare precursor cytotoxic T cells (pCTL). Delayed addition (2 weeks) of interleukin 2 induced T-cell proliferation, and a bulk culture (T-cell line) was obtained 2 days later. This T-cell line displayed cytotoxicity against SBN-1. A CD8+ CD4- cytotoxic T-cell clone (CT5) was then obtained that recognized SBN-1 but not autologous EBV+ B-lymphoblastoid cells, autologous T PHA-blasts, or Daudi, Raji, K562, and 11 allogeneic myeloma cell lines. Moreover, CT5 cytotoxic activity against SBN-1 was blocked by monoclonal antibodies recognizing human lymphocyte antigen class I molecules. This seems to be the first demonstration of myeloma-specific pCTL in peripheral blood T cells of patients with multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10100725

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  Deregulated cytokine network and defective Th1 immune response in multiple myeloma.

Authors:  M A Frassanito; A Cusmai; F Dammacco
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

2.  Regulation of cell adhesion and migration by Kindlin-3 cleavage by calpain.

Authors:  Yongzhong Zhao; Nikolay L Malinin; Julia Meller; Yi Ma; Xiaoxia Z West; Kamila Bledzka; Jun Qin; Eugene A Podrez; Tatiana V Byzova
Journal:  J Biol Chem       Date:  2012-09-25       Impact factor: 5.157

3.  T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Authors:  David J Chung; Katherine B Pronschinske; Justin A Shyer; Sneh Sharma; Samantha Leung; Shane A Curran; Alexander M Lesokhin; Sean M Devlin; Sergio A Giralt; James W Young
Journal:  Cancer Immunol Res       Date:  2015-10-13       Impact factor: 11.151

4.  Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis.

Authors:  Rebeca Pérez de Diego; Vanessa Sancho-Shimizu; Lazaro Lorenzo; Anne Puel; Sabine Plancoulaine; Capucine Picard; Melina Herman; Annabelle Cardon; Anne Durandy; Jacinta Bustamante; Sivakumar Vallabhapurapu; Jerónimo Bravo; Klaus Warnatz; Yves Chaix; Françoise Cascarrigny; Pierre Lebon; Flore Rozenberg; Michael Karin; Marc Tardieu; Saleh Al-Muhsen; Emmanuelle Jouanguy; Shen-Ying Zhang; Laurent Abel; Jean-Laurent Casanova
Journal:  Immunity       Date:  2010-09-09       Impact factor: 31.745

Review 5.  Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.

Authors:  D Atanackovic; T Luetkens; N Kröger
Journal:  Leukemia       Date:  2013-10-23       Impact factor: 11.528

6.  Antigens shared by malignant plasma cells and normal B cells may be involved in graft versus myeloma.

Authors:  P A Holloway; N Kaldenhoven; H M Kok-Schoemaker; B Van Kessel; W T M Van Blokland; A C Bloem; H M Lokhorst
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

7.  Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood.

Authors:  Melina Herman; Michael Ciancanelli; Yi-Hung Ou; Lazaro Lorenzo; Maja Klaudel-Dreszler; Elodie Pauwels; Vanessa Sancho-Shimizu; Rebeca Pérez de Diego; Avinash Abhyankar; Elisabeth Israelsson; Yiqi Guo; Annabelle Cardon; Flore Rozenberg; Pierre Lebon; Marc Tardieu; Edyta Heropolitanska-Pliszka; Damien Chaussabel; Michael A White; Laurent Abel; Shen-Ying Zhang; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2012-07-30       Impact factor: 14.307

8.  Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients.

Authors:  H Reinhard; S Yousef; T Luetkens; B Fehse; B Berdien; N Kröger; D Atanackovic
Journal:  Blood Cancer J       Date:  2014-05-09       Impact factor: 11.037

9.  Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant.

Authors:  David J Chung; Sneh Sharma; Madhumitha Rangesa; Susan DeWolf; Yuval Elhanati; Karlo Perica; James W Young
Journal:  Blood Adv       Date:  2022-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.